Arrowhead Q2 revenue falls to $73.7 million; net loss of $132.7 million
Arrowhead Pharmaceuticals reported fiscal second-quarter results for the period ended March 31, 2026, with revenue of $73.7 million, down from $542.7 million a year earlier. The company posted a net loss attributable to Arrowhead of $132.7 million, or $0.93 per diluted share, compared with net income of $370.4 million, or $2.75 per diluted share, a year earlier. The filing also cites two concurrent public offerings with gross proceeds totaling $930 million.
Key points
- Revenue was $73.7 million for the quarter, versus $542.7 million in the same period a year earlier.
- Net loss attributable to Arrowhead was $132.7 million, or $0.93 per diluted share, versus net income of $370.4 million, or $2.75 per diluted share.
- Two concurrent offerings raised $930 million gross, including $700 million of 0.00% convertible senior notes due 2032 and $230 million of common stock at $64.50 per share.
- Research and development expense rose to $173.3 million from $133.1 million.
The filing
Written by AI on Nov 8, 2026, 1:17 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 07, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.